Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2015', provides an overview of the Onychomycosis (Tinea Unguium)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Onychomycosis (Tinea Unguium)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Onychomycosis (Tinea Unguium) Overview 8
Therapeutics Development 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis 10
Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 11
Onychomycosis (Tinea Unguium) - Therapeutics under Investigation by Universities/Institutes 13
Onychomycosis (Tinea Unguium) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Onychomycosis (Tinea Unguium) - Products under Development by Companies 18
Onychomycosis (Tinea Unguium) - Products under Investigation by Universities/Institutes 19
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 20
Actavis plc 20
Anacor Pharmaceuticals, Inc. 21
Eisai Co., Ltd. 22
Evolva SA 23
Helix BioMedix, Inc. 24
Mayne Pharma Group Limited 25
Meiji Seika Pharma Co., Ltd. 26
Moberg Pharma AB 27
NAL Pharmaceuticals Ltd. 28
Nihon Nohyaku Co., Ltd. 29
Novabiotics Ltd 30
Nuvo Research Inc. 31
Viamet Pharmaceuticals, Inc. 32
Onychomycosis (Tinea Unguium) - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
albaconazole - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AN-2718 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
E-1224 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ELS-160 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
EV-086 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HB-1275 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
itraconazole - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
luliconazole - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ME-1111 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
NAL-3216 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NP-213 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules for Fungal Infections - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
terbinafine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
terbinafine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VT-1161 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 64
Onychomycosis (Tinea Unguium) - Dormant Projects 70
Onychomycosis (Tinea Unguium) - Discontinued Products 72
Onychomycosis (Tinea Unguium) - Product Development Milestones 73
Featured News & Press Releases 73
Sep 17, 2014: Moberg Pharma Announces Successful Results for MOB-015 in a Phase II Study for the Treatment of Onychomycosis 73
Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014 73
Dec 13, 2013: Moberg Pharma reports positive interim results in phase II clinical study of MOB-015 74
May 27, 2013: Moberg Pharma Completes Enrollment In Phase II Clinical Trial Of MOB-015 75
Nov 07, 2012: Moberg Derma Initiates Phase II Trial With MOB-015 For Treatment Of Onychomycosis 75
Jun 21, 2012: Mayne Pharma Receives MHRA Approval For Subacap 75
Mar 30, 2012: Palau Pharma Reports Positive Phase IIb Clinical Results Of Albaconazole For Treatment Of Onychomycosis At American Academy Of Dermatology Annual Meeting 76
Feb 14, 2012: NovaBiotics Receives US Patent Further Strengthening Novexatin 77
Feb 09, 2012: Moberg Derma Provides Update On Phase II Study Of MOB-015 77
Dec 15, 2011: Mayne Pharma Provides Update On Subacap European Marketing Approval Application 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80

List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2015 9
Number of Products under Development for Onychomycosis (Tinea Unguium) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Comparative Analysis by Unknown Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Investigation by Universities/Institutes, H1 2015 19
Onychomycosis (Tinea Unguium) - Pipeline by Actavis plc, H1 2015 20
Onychomycosis (Tinea Unguium) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 21
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co., Ltd., H1 2015 22
Onychomycosis (Tinea Unguium) - Pipeline by Evolva SA, H1 2015 23
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix, Inc., H1 2015 24
Onychomycosis (Tinea Unguium) - Pipeline by Mayne Pharma Group Limited, H1 2015 25
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 26
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2015 27
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 28
Onychomycosis (Tinea Unguium) - Pipeline by Nihon Nohyaku Co., Ltd., H1 2015 29
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2015 30
Onychomycosis (Tinea Unguium) - Pipeline by Nuvo Research Inc., H1 2015 31
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals, Inc., H1 2015 32
Assessment by Monotherapy Products, H1 2015 33
Number of Products by Stage and Target, H1 2015 35
Number of Products by Stage and Mechanism of Action, H1 2015 37
Number of Products by Stage and Route of Administration, H1 2015 39
Number of Products by Stage and Molecule Type, H1 2015 41
Onychomycosis (Tinea Unguium) Therapeutics - Recent Pipeline Updates, H1 2015 64
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2015 70
Onychomycosis (Tinea Unguium) - Dormant Projects (Contd..2), H1 2015 71
Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2015 72